By Doug Macron

Roche this week said it will shut down its in-house RNAi-related research activities as part of a broader cost-savings initiative that will include cutting its workforce by 6 percent over the next two years.

The company, which had been one of a handful of big pharmas to invest heavily in RNAi as a therapeutic modality, said it is responding to "mounting cost pressures in healthcare" and to "increasing hurdles for the approval and pricing of new medicines."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.